[PDF] Committee for Medicinal Products for Human Use (CHMP) recommends approval of siponimod (Mayzent) for treatment of multiple sclerosis

Source:
European Medicines Agency - EMA
Publisher:
European Medicines Agency
Publication date:
15 November 2019

Abstract

Siponimod is a selective immunosuppressant acting as a sphingosine 1-phosphate receptor modulator on lymphocytes, thus reducing the recirculation of T-cells into the central nervous system and limiting central inflammation.